4 Results for "

FOLR1+ cancers

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "FOLR1+ cancers" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P99225
CAS No.: 1453084-36-0
Synonyms: M9346A

Research Areas:  

Cancer

Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99225A
CAS No.: 1453084-36-0
Synonyms: M9346A (powder)

Research Areas:  

Cancer

Mirvetuximab (M9346A) (powder) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab (powder) is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
loading...
    loading...
Cat. No.: HY-P990941
CAS No.: 2853518-94-0
Synonyms: F131; GEN1184 antibody

Target:  

Antifolate

Research Areas:  

Inflammation/Immunology

Rinatabart (F131) is an IgG1-κ human antibody targeting FOLR1, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001). The Fc region of Rinatabart is engineered to reduce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. The KD values of Rinatabart binding to human FOLR1 in two sets of BLI assays are 1.528 nM and 5.296 nM, respectively. Rinatabart shows significantly lower affinity for FOLR2 and mouse FOLR1, and no reliable specific binding to FOLR3 and rat FOLR1. Rinatabart can be used in studies of FOLR1 targeting and antibody-drug conjugates .
loading...
    loading...
Cat. No.: HY-P992004
Synonyms: RA15-7, HuRA15-7Acc

Target:  

Folate Receptor (FR)

Research Areas:  

Cancer

KHK2805 (RA15-7) is a humanized antibody against folate receptor α (FOLR1), with a Kd of 0.647 nM for human FOLR1. KHK2805 binds to a unique epitope of FOLR1 and mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against FOLR1-expressing cells. KHK2805 exhibits cytotoxicity against both ovarian cancer cells and Platinum (HY-W096169D)-resistant ovarian cancer cells. KHK2805 can be used for the research of tumors such as ovarian cancer .
loading...
    loading...